Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: J Am Geriatr Soc. 2018 Oct 2;66(11):2188–2196. doi: 10.1111/jgs.15449

Figure 1.

Figure 1.

Meta-analyses of Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin trial (JUPITER) and Heart Outcomes Prevention Evaluation-3 (HOPE-3) for efficacy of rosuvastatin for primary atherosclerotic cardiovascular disease (ASCVD) prevention in older adults. (A) Effects of rosuvastatin on the composite endpoint of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in the JUPITER and HOPE-3 primary prevention trials. *Numbers of individuals at risk, incidence rates, and hazard ratios for nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in the JUPITER and HOPE-3 primary prevention trials, stratified according to age. (B) Meta-analysis within age subgroups of the JUPITER and HOPE-3 primary prevention trials evaluating the effects of rosuvastatin on the composite endpoint of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Reused with permission from Ridker PM et al. Primary Prevention With Statin Therapy in the Elderly. New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials. Circulation 2017;135:1979–1981. Available at https://www.ahajournals.org/journal/circ